Portola’s drug reverses effect of blood thinner Xarelto

(Reuters) – Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of an anticoagulant drug in a late-stage study, sending the company’s shares up 11 percent in premarket trading. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto, developed by Johnson & Johnson and Bayer AG, in healthy volunteers aged 50-75 years. Further data on the study is expected in mid-2015, Portola said on Friday. …
Go to Source